Literature DB >> 2144057

Suppression of human colorectal carcinoma cell growth by wild-type p53.

S J Baker1, S Markowitz, E R Fearon, J K Willson, B Vogelstein.   

Abstract

Mutations of the p53 gene occur commonly in colorectal carcinomas and the wild-type p53 allele is often concomitantly deleted. These findings suggest that the wild-type gene may act as a suppressor of colorectal carcinoma cell growth. To test this hypothesis, wild-type or mutant human p53 genes were transfected into human colorectal carcinoma cell lines. Cells transfected with the wild-type gene formed colonies five- to tenfold less efficiently than those transfected with a mutant p53 gene. In those colonies that did form after wild-type gene transfection, the p53 sequences were found to be deleted or rearranged, or both, and no exogenous p53 messenger RNA expression was observed. In contrast, transfection with the wild-type gene had no apparent effect on the growth of epithelial cells derived from a benign colorectal tumor that had only wild-type p53 alleles. Immunocytochemical techniques demonstrated that carcinoma cells expressing the wild-type gene did not progress through the cell cycle, as evidenced by their failure to incorporate thymidine into DNA. These studies show that the wild-type gene can specifically suppress the growth of human colorectal carcinoma cells in vitro and that an in vivo-derived mutation resulting in a single conservative amino acid substitution in the p53 gene product abrogates this suppressive ability.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2144057     DOI: 10.1126/science.2144057

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  500 in total

1.  p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication.

Authors:  J N Harada; A J Berk
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Exon shuffling mimicked in cell culture.

Authors:  A A van Rijk; W W de Jong; H Bloemendal
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

3.  CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase.

Authors:  E Vigo; H Müller; E Prosperini; G Hateboer; P Cartwright; M C Moroni; K Helin
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

4.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays.

Authors:  R Zhao; K Gish; M Murphy; Y Yin; D Notterman; W H Hoffman; E Tom; D H Mack; A J Levine
Journal:  Genes Dev       Date:  2000-04-15       Impact factor: 11.361

5.  Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53.

Authors:  A Seluanov; V Gorbunova; A Falcovitz; A Sigal; M Milyavsky; I Zurer; G Shohat; N Goldfinger; V Rotter
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

6.  The tumour suppressor protein p53 can repress transcription of cyclin B.

Authors:  K Krause; M Wasner; W Reinhard; U Haugwitz; C L Dohna; J Mössner; K Engeland
Journal:  Nucleic Acids Res       Date:  2000-11-15       Impact factor: 16.971

7.  E4orf6 variants with separate abilities to augment adenovirus replication and direct nuclear localization of the E1B 55-kilodalton protein.

Authors:  Joseph S Orlando; David A Ornelles
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

8.  Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis.

Authors:  Stijn Heessen; Ainars Leonchiks; Natalia Issaeva; Anatoly Sharipo; Galina Selivanova; Maria G Masucci; Nico P Dantuma
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

9.  Controlling tumor-derived and vascular endothelial cell growth: role of the 4Ff2 cell surface antigen.

Authors:  M Papetti; I M Herman
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

10.  Role for p53 in gene induction by double-stranded RNA.

Authors:  B T Hummer; X L Li; B A Hassel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.